Collectively, these results indicated that overexpression of FBXL7 can inhibit glucose metabolism by downregulating PFKFB4, thereby inhibiting the malignant phenotype of NSCLC cells. This evidence concerns the gene FBXL7 and non-small cell lung carcinoma.